Follow us on Twitter
twitter icon@FreshPatents


Psychiatric patents

      

This page is updated frequently with new Psychiatric-related patent applications.

Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
And the pharmaceutically acceptable salts thereof, wherein r1, r2, r2′, and x are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and hiv-associated neurocognitive disorders (hand). Compounds having formula (i) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-l-norleucine (don)..

Alkylated tetrahydroisoquinolines for binding to central nervous system receptors
Derivatives of 1,2,3,4-tetrahydroisoquinoline (thiq) having the general formula a-(ch2)n—b are provided, wherein a is thiq or a substituted derivative thereof and b is an aryl, cycloalkylaryl, or cycloalkyl group, wherein a and b are linked to each other by an alkyl or substituted alkyl chain. The compounds are useful as selective ligands (agonists or antagonists) of central nervous system receptors, and in particular of the seratonin receptors.
Florida A&m University


System and modifying biometric activity using virtual reality therapy
Systems and methods for using virtual reality content as therapeutic treatment of psychological, psychiatric or medical conditions of a user are provided. The system may comprise a vr device for displaying the vr content to the user and one or more biometric monitors for monitoring the user's biometrics before, during and/or after exposure to the vr content.
Storyup, Inc.


5-ht2c receptor agonists and compositions and methods of use
Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, prader-willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
Arena Pharmaceuticals, Inc.


7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to bdnf and trkb activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, rett syndrome, parkinson's disease, and alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof.
Emory University


Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the hpa axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription medication (e.g., percodan®, percoset®), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, adhd, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., prader willi syndrome), obesity, depression, menopause, premenstrual syndrome (pms), obsessive compulsive disorder (ocd), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.. .
Embera Neurotherapeutics, Inc.


Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University


Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
The present invention provides compounds of formula (i) that are pde1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention..
H. Lundbeck A/s


Substituted triazolo bicyclic compounds as pde2 inhibitors
The present invention is directed to substituted triazolo bicyclic compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction..
Merck Sharp & Dohme Corp.


Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
The present invention is directed to pyrimidine carboxamide compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction..
Merck Sharp & Dohme Corp.


Pyridine and pyrimidine derivatives

The compounds of formula i may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .

Heterocyclic compounds for the treatment of neurological and psychological disorders

Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
Alkermes Pharma Ireland Limited

Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders

The invention is directed to the use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders.. .
New York University

Sublingual administration of riluzole

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided.
Biohaven Pharmaceutical Holding Company Limited (b

Sublingual formation of riluzole

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided.
Biohaven Pharmaceutical Holding Company Limited (b

Dihydropyrazolopyrimidinone compounds as pde2 inhibitors

The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (i) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction..
Msd R & D (china) Co. Ltd.

Heteroarylphenoxy benzamide kappa opioid ligands

And pharmaceutically acceptable salts thereof wherein the variables r1, r2, r3, r4, r9, x, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.. .

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. .
Acorda Therapeutics, Inc.

Bicyclic heterocyclic compounds as pde2 inhibitors

The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (i) and (ii) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction..
Merck Sharp & Dohme Corp.

Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration

A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.. .
Phovitreal Pty Ltd

Feedback brain stimulation to enhance sleep spindles, modulate memory and cognitive function, and treat psychiatric and neurological symptoms

The present invention relates to methods for modulating bursts of oscillatory brain activity, such as sleep spindles, in a subject. The invention further relates to methods of improving memory or cognitive function in a subject and method of modulating or enhancing the frequency of occurrence, structure, amplitude, and/or synchronization of sleep spindles in a subject by detecting a burst of oscillatory brain activity in the subject and passing an oscillating current through the skull of the subject..
The University Of North Carolina A! Chapel Hill

6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors

The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (i) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction..
Msd R & D (china) Co. Ltd.

Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use

Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.. .
University Of Belgrade - Faculty Of Pharmacy

Pupil distortion measurement and psychiatric diagnosis method

A prediction, diagnosis, or suggesting of a diagnosis of a psychiatric disorder is made based in embodiments of the disclosed technology by determining a shape of one or both pupils in an image of a patient. Such a diagnosis can be made in real-time by diagnosing the patient, or by viewing a digitized version of the patient's face as part of post-processing.

Pro-neurogenic compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The Univeristy Of Texas System

Imidazole derivatives

The compounds of formula i may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .

Biomarker for psychiatric and neurological disorders

The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders.
Resvo Inc.

Substituted imidazopyridine and triazolopyridine analogs as positive allosteric modulators of muscarinic acetylcholine receptor m1

In one aspect, the invention relates to substituted imidazopyridine and triazolopyridine analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Imidazole derivatives

Or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof for use in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .

Compositions and methods for treating depression

Disclosed are a novel combination of specific therapeutics selected from s-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression..
Alexander Vuckovic, M.d., Llc

Synergistic combinations of caffeine, ginkgo biloba and beta-phenylethylamine

The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, ginkgo biloba, and β-phenylethylamine (pea) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof..
Trinutra Ltd.

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company

Abbvie Inc.

. .

1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

And pharmaceutically acceptable salts thereof, wherein a, ra, r1, r2, r3, r4, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..

Potent and selective inhibitors of monoamine transporters; making; and use thereof

Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (da), serotonin (5-ht), and/or norepinephrine (ne) reuptake via their respective transporters, dat, sert and net.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Vigor enhancement via administration of pyrimidine derivatives

Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation.
University Of Central Florida Research Foundation, Inc.

Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Disclosed herein are substituted 8-aminothieno[3,2-e][1,2,4]triazolo[4,3-b]pyridazine-7-carboxamide compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions..
Vanderbilt University

Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline

The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, and its use for the treatment of a) psychiatric disorders with prominent cognitive deficits e.g. Chronic ptsd (post traumatic stress disorder); b) non-degenerative disorders with prominent cognitive deficits e.g.
Axovant Sciences Gmbh

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Regulatory brain specific ctyoplasmic rnas (bc rnas) and methods of use thereof in diagnosis and treatment of neuropsychiatric lupus

Compositions and methods for diagnosing an increased risk of npsle are provided.. .
The Research Foundation For State University Of New York

5ht3 receptor antagonists

That are 5-ht3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..

Selective fkbp51 ligands for treatment of psychiatric disorders

The present invention relates to compounds having a selective fkbp51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective fkbp51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions..
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.

Diphenethylamine derivatives which are inter alia useful as analgesics and their production

Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurode-generative, psychiatric and neuropsychiatric disorders, and also as anti-itch, anti-addiction, anti-inflammatory, anti-obesity, anti-epileptic, anti-convulsant, anti-seizure, anti-stress, anti-psychotic and anti-depressant medications and their pharmaceutically acceptable salts and easily accessible derivatives thereof (e.g. Esters, ethers, amides), processes for their preparation and their application in the manufacture of pharmaceutical products..
University Of Innsbruck

Methods and compositions for mitochondrial replacement therapy

The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities..
The Mclean Hospital Corporation

Pharmaceutical composition for treating posttraumatic stress disorder

Provided are a posttraumatic stress disorder (ptsd) animal model in which dopamine receptor subtype 4 (d4r) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating ptsd using the same, and a pharmaceutical composition for treating ptsd comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (ltd), the understanding of pathogenesis of ptsd may be heightened, the animal model exhibiting similar clinical conditions of ptsd and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for ptsd and screening of a therapeutic drug.
Postech Academy-industry Foundation

Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

And pharmaceutically acceptable salts thereof, wherein ring b, a1, a2, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..

Isoquinoline amide and isoquinoline amide-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mglur4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.. .
Vanderbilt University

Benzomorpholine and benzomorpholine-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mglur4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.. .
Vanderbilt University

Pyrazolyl pyrimidinone compounds as pde2 inhibitors

The present invention is directed to pyrimidine carboxamide compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction..
Merck Sharp & Dohme Corp.

Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder

The invention involves inducing a plurality e.g., 3-50 or more mutations (e.g., any whole number between 3 and 50 or more of mutations, with it noted that in some embodiments there can be up to 16 different rna(s), e.g., sgrnas each having its own a promoter, in a vector, such an aav vector or a lentiviral vector and that when each sgrna does not have its own promoter, there can be twice to thrice that amount of different rna(s), e.g., sgrnas, e.g., 32 or even 48 different guides delivered by one vector) in transgenic cas9 eukaryotes to model a neuronal disease or disorder. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof.
Massachusetts Institute Of Technology

Diagnostic pediatric acute-onset neuropsychiatric syndrome (pans) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (pans) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (pandas) in an individual. These include enzyme linked immunosorbent assays (elisas) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor d1, dopamine receptor d2, serotonin receptor 5ht2a, and serotonin receptor 5ht2c.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Substituted pyrazino[2,2-a]isoquinoline derivatives

The present invention relates to compounds of formula of formula i wherein r, r1, r2 and l are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.

Abbvie Deutschland Gmbh & Co. Kg

. .

Compounds and compositions and uses thereof

And pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed..

Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Disclosed herein are thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridin-6-amine, thieno[3,2-e][1,2,4]triazolo[4,3-a]pyridin-3-amine, and imidazo[1,2-a]thieno[3,2-e]pyridin-3-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions..
Vanderbilt University

Compounds and compositions and uses thereof

Are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need thereof are also disclosed..

Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mglur4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.. .
Vanderbilt University

Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mglur4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.. .
Vanderbilt University

Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mglur4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.. .
Vanderbilt University

Process for the preparation of histamine h3 receptor modulators

The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. .
Janssen Pharmaceutica Nv

Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mglur4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.. .
Vanderbilt University

Substituted pyridazine carboxamide compounds

The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against alk and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases.. .
Xcovery Holding Company Llc

Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

A method for the treatment of a neurodegenerative, psychiatric or neurological disease associated with a cholinergic deficit comprising administering gln-1062 or a pharmaceutically acceptable salt thereof by nasal administration to a patient in need thereof.. .
Neurodyn Life Sciences Inc.

Compositions and methods for treating anxiety and compulsive behavior

Provided herein is compositions and methods for treating anxiety, obsession and/or pathologically compulsive behavior associated with various neuropsychiatric diseases.. .
University Of Iowa Research Foundation

Aesthetic biological structure treatment by magnetic field

Methods and devices producing time varying magnetic field treats a patient. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch.
Btl Holdings Limited

1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors

The present invention provides 1h-pyrazolo[4,3-b]pyridin-7-amines of formula (i) as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders

The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (cns) disorders, including depression and anxiety.. .
Neurovance, Inc.

Method and computer modeling of the interaction between and among cortical and subcortical areas in the human brain for the purpose of predicting the effect of drugs in psychiatric and cognitive diseases

Computer modeling of interactions between and among cortico and subcortical areas of the human brain predicts the effect of drugs in psychiatric and cognitive diseases on one or more clinical scales. Diseases that can be modeled include psychiatric disorders, such as schizophrenia, bipolar disorder, major depression, adhd, autism, obsessive-compulsive disorder, substance abuse and cognitive deficits therein and neurological disorders such as alzheimer's disease, mild cognitive impairment, parkinson's disease, stroke, vascular dementia, huntington's disease, epilepsy and down syndrome.
Terra Nova Nurseries, Inc.

Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3, 2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions..
Vanderbilt University

5,5-bicyclic oxazole orexin receptor antagonists

The present invention is directed to 5,5-bicyclic oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Ethyldiamine orexin receptor antagonists

The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Pyrrolidine orexin receptor antagonists

The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Magnetic field stimulation

A magnetic coil system featuring a multi-layer structure, a spherical shape, or both allows for efficient generation of a gradient magnetic field that induces an electric field in air in a region proximate to the coil. By subjecting at least a portion of a person's brain to the induced electric field various psychiatric disorders can be treated..
The Mclean Hospital Corporation

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company

. .

1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders

Wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.

Piperidine isoxazole and isothiazole orexin receptor antagonists

The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Methods for treating psychiatric disorders

Methods for treating subjects afflicted with a psychiatric disorders [e.g., autism spectrum disorder (asd), schizophrenia, and/or depression] are described herein. More particularly, the present invention relates to a method for treating a subject afflicted with or at risk for developing a psychiatric disorder (e.g., asd, of which autism is a particular example) that calls for selecting a subject afflicted with or at risk for developing the psychiatric disorder based in part on previous in utero exposure to maternal immune activation (mia) and treating the subject by administering pharmacological agents or implementing optogenetic tools or chemogenetic tools that correct dysregulated neuronal excitation/inhibition (e/i) ratios in cortical patches of the subject wherein the e/i ratio is dysregulated.

Composition and treatment of neuropsychiatric disorders

The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but not limited to, psychostimulant use disorder (pud) and other substance-related additive disorders, post-traumatic stress disorder (ptsd) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (lid) and other types of dyskinesias. The present specification shows specific examples of a dosage form..
Duke University

Hydroxmethyl piperidine orexin receptor antagonists

The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Bridged diazepane orexin receptor antagonists

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Oxazole orexin receptor antagonists

The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Amidoethyl azole orexin receptor antagonists

The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Pyrazole, triazole and tetrazole orexin receptor antagonists

The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Piperidine oxadiazole and thiadiazole orexin receptor antagonists

The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Pyrazole orexin receptor antagonists

The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject..

Systems and methods for generating biomarkers based on multivariate classification of functional imaging and associated data

Systems and methods for generating biomarkers associated with neuropsychiatric disorders, neurodevelopmental disorders, neurobehavioral disorders, or other neurological disorders are described. In general, the biomarkers are generated based on correlations between functional imaging data and clinical acquired from a subject, as computed using a multivariate classifier.
The Brigham And Women's Hospital, Inc.

Methyl diazepane orexin receptor antagonists

The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors

The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (i) and pharmaceutical compositions containing them. Moreover, the compounds of formula (i) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals.
Domain Therapeutics

Pro-neurogenic compounds

Compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, parkinson's disease, alzheimer's disease, down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like..
Board Of Regents Of The University Of Texas System

7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto

Bdnf and trkb activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, rett syndrome, parkinson's disease, and alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs..

Systems and methods for treating a psychiatric disorder

Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed.
Icahn School Of Medicine At Mount Sinai

Triazolopyrazinones as pde1 inhibitors

The present invention provides triazolopyrazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .

Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation

The invention relates to a compound comprising the following general formula (1) for use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (1) wherein each of r1, r2 and r3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle or heteroaryl.. .

Imidazopyrazinones as pde1 inhibitors

The present invention provides imidazopyrazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors

The present invention provides 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones of formula (i) as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Methods for enhancing permeability to blood-brain barrier, and uses thereof

Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (bbb) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (vegf), insulin-like growth factor i (igf-1), igf-ii, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent.
Academia Sinica

Dosing regimen for missed doses for long-acting injectable paliperidone esters

The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of the 3-month formulation of paliperidone palmitate.. .
Janssen Pharmaceuticals, Inc.

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. .
Acorda Therapeutics, Inc.

4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators

The disclosures herein relate to novel compounds of formula wherein r1, r2, r3 and r4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mglu5 receptor function.. .
Heptares Therapeutics Limited

Quinazolin-thf-amines as pde1 inhibitors

The present invention provides quinazolin-thf-amines as pde i inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

5-ht3 receptor antagonists

Which are useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..

Methyl oxazole orexin receptor antagonists

The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Heteroaryl orexin receptor antagonists

The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Devices, treatment of neuropsychiatric disorders

The present disclosure relates to methods, devices and systems used for the treatment of mood, anxiety, post traumatic stress disorder, and cognitive and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“tns”). More specifically, cutaneous methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, infraorbital, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein..
The Regents Of The University Of California

Transgenic mouse model for conditional fkbp51 expression and related methods

The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human fkbp51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline transactivator (tta) operably linked to a promoter; wherein the tta is expressed upon activation of the promoter and binds the tetracycline response element, thereby causing expression of fkbp51.
University Of South Florida

Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with neuroinflammatory and neurodegenerative basis

An ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such as depression and schizophrenia.. .
Universita' Degli Studi Di Cagliari

Method and system to predict response to treatments for mental disorders

The present inventions relates to methods and assays to predict the response of an individual to psychiatric treatment and to a method to improve medical treatment of a disorder, which responsive to treatment with a psychiatric treatment.. .
Pathway Genomics Corporation

Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

The present invention provides a novel chromone oxime derivative of formula (i), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders..
Prexton Therapeutics Sa

Systems level state characteristics in experimental treatment of disease

Methods and system for assessment of a state of the central nervous system (cns) of a subject and/or differentiation between states of the cns at a specific time point based on electrophysiological recordings of signals from at least two anatomical structures, wherein the signals are recorded from recording sites located in the anatomical structures, wherein the electrophysiological recordings comprise spatiotemporal fluctuations in the recorded extracellular potential, wherein the electrophysiological recordings are action potentials and/or local field potentials (lfps) in the anatomical structures and represent the state of the cns, a s well as the use of the method for assessment of a state of the cns and/or differentiation of at least two states of the cns, as well as to the use of the method for evaluating the effect of a treatment of a condition or disease, wherein the condition or disease is neurological and/or psychiatric.. .

Substituted 4-alkoxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Method of treating organophosphate intoxication

The present invention provides new compositions and methods for treating and/or reversing organophosphate intoxication, manifested by both cholinergic and non-cholinergic crisis, in a mammal resulting from exposure to organophosphate compounds. The neurosteroidal compounds of this invention are those having the general structural formula of pregnane, androstane, 19-norandrostanes, and norpregnane with further moieties as defined herein.
The Texas A&m University System

Amphiphilic compounds with neuroprotective properties

Amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use in methods of treatment of neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of cns, neurodegenerative changes and disorders of cns, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing compound.. .
Fyziologicky Ustav Av Cr, V.v.i.

N-substituted-5-substituted phthalamic acids as sortilin inhibitors

The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as alzheimer's disease and parkinson's disease.. .

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company

Treating various disorders using trkb agonists

Novel compounds and methods for activating the trkb receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted c5 or c6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof.
Emory University

Macrocyclic kinase inhibitors and uses thereof

The present disclosure provides macrocyclic compounds of formula (i). The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof.
Dana-farber Cancer Institute, Inc.

Therapeutic isoxazole compounds

Wherein a1, a2, a3, r1, x, y, and b have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase b (mao-b) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals..

Imidazolyl kinase inhibitors and uses thereof

The present disclosure provides imidazolyl compounds of formula (i) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof.
Dana-farber Cancer Institute, Inc.

Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation

The invention relates to a compound comprising the following general formula (1) and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of r1, r2 and r3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.. .
Universitat Bern

Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof

The subject matter of the invention furthermore relates to a novel, stereoselective synthesis for the preparation of the novel enantiomer derivatives according to the invention. The novel medicinal and/or pharmaceutical compositions comprising these enantiomers are suitable for the treatment of the named diseases, and the enanatiomers are used for manufacture of these compositions.

Allosteric modulators of cb1 cannabinoid receptors

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (cb1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the cb1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.. .
Northeastern University

2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.. .

Method of treatment of schizophreniform disorder

Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders.
Curemark, Llc

Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent..
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor

The present invention is directed to 6,7-dihydro-5h-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the m4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which m4 muscarinic acetylcholine receptors are involved.

Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.. .
Merck Patentgesellschaft

Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors

Their use as allosteric modulators of mglur5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.. .

Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent..
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

Exo-s-mecamylamine formulation and use in treatment

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg.
University Of South Florida

Compositions and methods for treating neurodegenerative diseases

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as huntington's disease, parkinson's disease, and alzheimer's disease..
Azevan Pharmaceuticals, Inc.

Botulinum toxin treatments of neurological and neuropsychiatric disorders

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder..
Allergan, Inc.

Substituted imidazo[1,5-a]pyrazines as pde9 inhibitors

The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (i). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (i)..

Methods for diagnosing and treating neuroimmune-based psychiatric disorders

The methods of the present invention are useful for determining whether an individual has or is at risk of developing a neuroimmune-based psychiatric disorder by detecting the expression level of one or more cytokine receptors in a biological sample. The methods of the present invention are also useful for the in vivo imaging of brain tissue by detecting one or more imaging agents such as ligands (e.g., cytokines) that bind to one or more cytokine receptors.
The Regents Of The University Of California

Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions

The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof, in which r1, r2, r3, r4 and r5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. .
Takeda Pharmaceutical Company Limited

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-i

The present invention relates to chemical compounds of formula (i), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nachr). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7 nachr is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases..
Merck Sharp & Dohme Corp.

Anti-depression compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The University Of Texas System

Mecp2e1 gene

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders..
Centre For Addiction And Metal Health

Substituted pyrazino[2,2-a]isoquinoline derivatives

The present invention relates to compounds of formula of formula i wherein r, r2and l are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.. .

Substituted azetidine derivatives

The present invention relates to compounds of formula of formula i wherein r, r1. R2, r2′, r3, r4, r5, l1, l2 and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i..

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring mechanism

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

Mecp2e1 gene

The invention is a novel mecp2e1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders..
Centre For Addiction And Mental Health

2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives

The present invention relates to compounds of formula of formula i wherein x, l and r1 are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.

6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives

The present invention relates to compounds taar receptor antagonists of formula i wherein x, r, l, ar and r1 are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.

Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin a for the treatment of neuropsychiatric and addictive disorders

Methods of treating neuropsychiatric disorders including affective disorders and addiction involve intranasal or transdermal administration of a substantially selective kappa-opioid-receptor agonist that is also a partial d2 agonist, such as the compound salvinorin a. Also disclosed are intranasal, transdermal and/or inhalation systems for delivering the kappa-opioid-receptor agonist..

Multiple biomarker panels to stratify disease severity and monitor treatment of depression

Materials and methods for identifying and measuring pharmacodynamic biomarkers of neuropsychiatric disease (e.g., major depressive disorder), stratifying disease severity, and monitoring a subject's response to treatment are provided.. .
Vindrauga Holdings, Llc

Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1

In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Trpm8 antagonists

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.. .

Pattern analysis based on fmri data collected while subjects perform working memory tasks allowing high-precision diagnosis of adhd

Using a plurality of distinct behavioral tasks conducted in a functional magnetic resonance imaging (fmri) scanner, fmri data acquired from one or more subjects performing working memory tasks can be used for diagnosing psychiatrics and neurological disorders. A classification algorithm can be used to determine a classification model, tune the model, and apply the model.
Northwestern University

Orexin receptor antagonists

Wherein w, x and y1, y2, y3 and y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.. .

System and diagnosis and treatment of neuropsychiatric disorders

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered bh4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder.
The Research Foundation For Mental Hygiene, Inc.

Substituted prolines / piperidines as orexin receptor antagonists

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.

Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases

Tetrahydroprotoberbine (thpb) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-thpbs of general formula (i).

Novel tricyclic modulators of cannabinoid receptors

The compounds of the invention are modulators of cannabinoid receptors cb1 or cb2. The compounds can be used for the prevention or treatment of, e.g., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases.
The University Of Montana

Engineered light-activated anion channel proteins and methods of use thereof

Aspects of the disclosure include compositions, devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering light-responsive polypeptides, or nucleic acids encoding same, to target cells.
The Board Of Trustees Of The Leland Stanford Junior University

Peptides as oxytocin agonists

The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.

Peptides as oxytocin agonists

The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .
Hoffmann-la Roche Inc.

Pde9 inhibitors with imidazo triazinone backbone

This invention is directed to compounds, which are pde9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
H. Lundbeck A/s

Serotonin receptor-targeting compounds and methods

This invention relates to, in part, compositions and methods that are useful for, inter alia, the treatment of various diseases, including those linked to binding at a serotonin receptor. The compositions include chiral tetrahydronaphthalen-2-amine derivatives.
Northeastern University

Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain

The invention provides methods and compositions for the treatment of a subject having a psychiatric disease or dis order based upon the subject's genotype and/or the number of risk alleles carried by the subject, which risk alleles have been found by the present inventors to predispose a subject to antipsychotic medication induced weight gain (aiwg). The methods of the inven tion also provide for different treatments, or different treatment regimens, for the subject depending on the subject's risk of aiwg.
Centre For Addiction And Mental Health

Suprametallogels and uses thereof

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology

Magnetic stimulation methods and devices for therapeutic treatments

Methods and devices producing time varying magnetic field have therapeutic uses. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch.
Btl Holdings Limited

5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives

The present invention relates to compounds of formula of formula i wherein x, ar, r1, m and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.

Composition for use in treating and/or preventing human condition, disorder or diseases

Composition comprising a metal and/or a semimetal, a sodium salt, a tranquilizer, a halogen, a carotenoid, grain, and a neutral gel for example for use in treating and/or preventing a condition, disorder or disease such as pain, metabolic diseases, fatigue, absence of appetite, cramps, immune diseases, inflammatory disease, cancer, neurological and/or psychiatric diseases.. .

Methods and compositions for mitochondrial replacement therapy

The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities..
The Mclean Hospital Corporation

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company

Process for the preparation of histamine h3 receptor modulators

The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. .
Janssen Pharmaceutica Nv

Extracranial implantable devices, the treatment of neuropsychiatric disorders

The present disclosure relates to methods, devices, and systems used for the treatment of mood, anxiety, cognitive, and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“tns”). More specifically, minimally invasive systems, devices and methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein..
Neurosigma, Inc.

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to prove the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. .
Acorda Therapeutics, Inc.

Method and system to predict response to treatments for mental disorders

The present inventions relates to methods and assays to predict the response of an individual to a psychiatric treatment and to a method to improve medical treatment of a disorder, which is responsive to treatment with a psychiatric treatment.. .
Pathway Genomics Corporation

Methods and pharmaceutical compositions for the treatment of symptoms of anxiety and panic using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations

The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist.
Thomas P. Dooley, Phd.

Pharmaceutical salts of an orexin receptor antagonist

The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Morpholin-pyridine derivatives

The present invention relates to compounds of formula of formula i wherein x, r, l, ar, r1 and n are as described herein, compositions containing compounds of formula i, methods of manufacture of compounds of formula i and methods of treating psychiatric disorders with compounds of formula i.. .
Hoffmann-la Roche Inc.

Cb2 receptor ligands for the treatment of psychiatric disorders

The present invention provides cannabinoid type 2 (cb2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-o-methylhonokiol for treating attention deficit hyperactivity disorder (adhd) and tourette's syndrome..
Ariel - University Research And Development Company, Ltd.

Method for cross-diagnostic identification and treatment of neurologic features underpinning mental and emotional disorders

A system and method for diagnosing mental or emotional disorders is disclosed. An affective bci component is incorporated into a closed loop, symptom—responsive psychiatric dbs system.
Massachusetts Institute Of Technology

Technologies for diagnosing neurological or psychiatric illnesses

A technology which enables identifying, via a computer, a vessel in a third image. The third image is obtained from a subtraction of a second image from a first image.
The Trustees Of Columbia University In The City Of New York

System and diagnosis and treatment of neuropsychiatric disorders

An assay for a gch1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the gch1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered bh4 system measures, is used to screen or diagnose subjects at risk for developing a psychiatric, neuropsychiatric, or neurological disorder.
The Research Foundation For Mental Hygiene, Inc.

Guanidine compounds and use thereof as binding partners for 5-ht5 receptors

Corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-ht5 receptors for the treatment of diseases which are modulated by a 5-ht5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions..

Methods and compositions for the treatment of post-traumatic stress disorder

Methods and compositions are disclosed to treat neuropsychiatric disorders post-traumatic stress disorder (ptsd). In particular, described herein are angiotensin receptor blockers (arbs), and in particular the combination of one or more arb (such as telmisartan) and an agent that enhances the delivery of the arb across the blood-brain barrier (such as minocycline).

Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Halogenated quinazolin-thf-amines as pde1 inhibitors

The present invention provides halogenated quinazolin-thf-amines as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

In one aspect, the invention relates to n-substituted 3,4-dihydro-benzo[£][1,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Compositions and methods for treatment of psychiatric disorders

Compositions and methods for the treatment of a unipolar depression containing betaine, and folate. Formulations for oral administration optionally also contain l-methionine..

In vitro diagnosing parkinson's disease

The present invention relates to an in vitro method of diagnosing a neurological disease associated with at least one symptom selected from the group comprising non-motor symptoms, sleep-wake disorders, sensory disorders, neuropsychiatric disorders and cognitive difficulties, comprising measuring the amount of active c-rel factor in a biological sample comprising endogenus c-rel factor from a patient.. .
Fondezione Ospedale Hospital In Venice

Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions..
Max-planck-gesellschaft Zur Forderung Der Wissensc Haften E.v.

1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

And pharmaceutically acceptable salts thereof, wherein a, ra, r1, r2, r3, r4, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..

Magnetic stimulation methods and devices for therapeutic treatments

Methods and devices producing time varying magnetic field have therapeutic uses. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch.
Btl Holdings Limited

Magnetic stimulation methods and devices for therapeutic treatments

Methods and devices producing time varying magnetic field have therapeutic uses. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch.
Btl Holdings Limited

Uses of paralog-selective inhibitors of gsk3 kinases

The present disclosure provides methods of using gsk3α-selective inhibitors for treating fragile x syndrome, attention deficit hyperactivity disorder (adhd), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (aml), autism, and psychiatric disorder. The gsk3α-selective inhibitors include compounds of formula i-a.
Massachusetts Institute Of Technology

2-pyridyloxy-4-methyl orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-4-methyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-methyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Pro-neurogenic compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The Univeristy Of Texas System

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Hexahydrofuropyrroles as pde1 inhibitors

The present invention provides hexahydrofuropyrroles as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Compositions and methods for the treatment of addiction and other neuropsychiatric disorders

The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (hpa) axis and at least one active ingredient that targets the prefrontal cortex.
Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College

S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by pde7

The present invention relates to a family of s-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (pde7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.. .
Consejo Superior De Lnvestigaciones Cientificas (csic)

Substituted (4'-hydroxyphenyl)cycloaklkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform

Disclosed are substituted (4′-hydroxylphenyl)cycloalkane compounds and there use as selective agonists of the estrogen receptor beta isoform (erβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat diseases associated with er activity, such as proliferative diseases and disorders and/or psychiatric diseases or disorders..
Concordia University Wisconsin

Lithium co-crystals for treatment of neuropsychiatric disorders

The invention concerns methods and compositions for treating a neuropsychiatric disorder, wherein the method comprises administering an effective amount of a co-crystal of lithium to a subject in need thereof, wherein the co-crystal comprises lithium, or a pharmaceutically acceptable salt thereof, and an amino acid.. .
University Of South Florida

Fluorinated arylalkylaminocarboxamide derivatives

Fluorinated arylalkylaminocarboxamide derivatives of formula (i) are described wherein w, j, n, r1, r2, r2′, r3, r4, r5 and r6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urolological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .
Newron Pharmaceuticals S.p.a.

Method of determining disease causality of genome mutations

A method of identifying a gene or genomic mutation that is linked to causality of a neuropsychiatric disorder is provided. The method comprises identifying exons which exhibit an expression level that is at least within the 75th percentile of exon expression levels within a nucleic acid-containing sample from a mammal having a neuropsychiatric disorder; comparing the sequence of each identified exon to the sequence of a corresponding exon from a healthy control to identify rare or de novo sequence mutations within the identified exon; calculating the burden of rare or de novo mutations within the exon; and determining the correlation between expression level of the identified exon and burden of de novo or rare mutations in the exon, wherein an inverse correlation indicates that the exon gene is linked to causality of the neuropsychiatric disorder..
The Hospital For Sick Children

N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders

The present invention relates to compounds of the general formula i wherein het, r1, r2, w and x are as defined herein. Compounds of formula i are useful for treating neuropsychiatric disorders..
Hoffmann-la Roche Inc.

Abbvie Inc.

. .

Piperidinyloxy lactone orexin receptor antagonists

The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Imidazopyrazinones as pde1 inhibitors

The present invention provides imidazopyrazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Diazepane orexin receptor antagonists

The present invention is directed to diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the diazepane compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Quinazolin-thf-amines as pde1 inhibitors

The present invention provides quinazolin-thf-amines as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

2-amino-3-ester-pyridyl orexin receptor antagonists

The present invention is directed to 2-amino-3-ester pyridyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-amino-3-ester pyridyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Thioether-piperidinyl orexin receptor antagonists

The present invention is directed to thioether-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thioether-piperidinyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Heterocyclic compounds for the treatment of neurological and psychological disorders

Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
Alkermes Pharma Ireland Limited

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.

Monitoring device and cognitive behavior therapy

A user monitoring device system includes a user monitoring device with a microphone and sensors to determine air quality, sound level/quality, light quality and ambient temperature near the user. A movement detection device detects a user's movement information.
Hello Inc.

Mlk inhibitors and methods of use

Provided are compounds having an inhibitory effect on mixed lineage kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by mixed lineage kinase inhibition.
The University Of Rochester

Imidazotriazinones as pde1 inhibitors

The present invention provides imidazotriazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.. .
H. Lundbeck A/s

Method and use of draining fluid above the cribriform plate

Alzheimer's disease is a neurological disorder marked by progressive memory and cognitive impairments that eventually result in death. Currently, there are no effective therapies or cures that slow or halt the relentless progression of alzheimer's disease.

D-methadone for the treatment of psychiatric symptoms

The present invention relates to a method of treating psychiatric symptoms in a subject having a nmda receptor and a ne receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the nmda receptor and ne receptor of the subject.. .
Relmada Therapeutics, Inc.

Transgenic animal model of mood disorders

A non-human transgenic animal having a polynucleotide encoding a ptn polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the ptn polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.. .
Brainco Biopharma, S.l.

2-pyridyloxy-3-ester-4-ether orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-3-ester-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

A pyrimidine derivative and a fatty acid source for use in the treatment of constipation

The invention relates to a combination of a pyrimidine derivative and a fatty acid source for use in the treatment of constipation, in particular in the treatment of constipation in patients suffering from gi disorders, neurological disorders, or psychiatric disorders. Advantageously, the combination comprises one or more vitamins or fibres..
N.v. Nutricia

Quinoline derivatives as pde10a enzyme inhibitors

The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10a over other pde subtypes.
H. Lundbeck A/s

Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Selective fkbp51 ligands for treatment of psychiatric disorders

The present invention relates to compounds of the general formula (i) having a selective fkbp51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective fkbp51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions..
Max-planck-gesellschart Zur FÖrderung Der Wissensc Haften E.v.

Delivery of drugs

The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases.
Nanomerics Ltd

Recombinant t-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (mhc) molecule including covalently linked first, second, and third domains; wherein the first domain is an mhc class ii β1 domain and the second domain is an mhc class ii α1 domain; or wherein the first domain is an mhc class i α1 domain and the second domain is an mhc class i α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system..
The United States Government As Represented By The Department Of Veterans Affairs

Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders

And pharmaceutically acceptable salts thereof, wherein ring b, a1, a2, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein..

Imidazole derivatives

As defined herein before useful for the treatment of psychiatric disorders.. .

System and emergency telepsychiatry using emergency psychiatric mental state prediction model

The present invention relates to an emergency psychiatric mental state prediction model-based emergency telepsychiatry system and a method for operating the same. The emergency telepsychiatry system can include a collection unit for collecting real-time mental health symptoms and medical and family history data of a patient, a prediction unit for predicting a psychiatric mental state of the patient from the collected real-time mental health symptoms and medical and family history data, and a transmission unit for providing the predicted psychiatric mental state of the patient..
University-industry Cooperation Group Of Kyung-hee University

Maternal th17 cells and psychiatric disorders

Methods are presented herein for reducing the risk of developing a psychiatric disorder (e.g., autism like disorder) in a fetus involving administering an inhibitor of t helper 17 (th17) cell activity to the mother of the fetus, while the mother is pregnant with the fetus at risk. Also encompassed herein is a method for treating a fetus in utero to reduce the risk of abnormal cortical development that arises from th17 cell-mediated activity..

5-ht3 receptor antagonists

Which are useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..

Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

The invention relates to methods of treating stress-sensitive psychiatric diseases arising from trauma in a subject by enhancing ghrelin signaling in the bla of the subject. The invention also relates to methods of reversing ghrelin resistance..
Massachusetts Institute Of Technology

Treatments for alzheimer's related diseases and disorders

The invention relates to a method for the treatment of neuropsychiatric behavioral symptoms in patients with alzheimer's disease wherein the symptoms are selected from the group consisting of anxiety, agitation, aggression, depression, hallucination, memory loss, confusion, repetition, sleep issues, sun downing, suspicion, delusions, and wandering, comprising the step of administering to the patient an effective amount of a compound of formula i, ia, ib, table 1, preferably compound-1, or a pharmaceutically acceptable salt thereof.. .
Alkermes, Inc.

Polypeptides and methods for modulating d1-d2 dopamine receptor interaction and function

The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal d1-d2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from d1-d2 coupling and/or activation.
Centre For Addiction And Mental Health

Sustained-release compositions comprising topiramate and an alkalizer

The present invention relates to a sustained release composition comprising topiramate and one or more pharmaceutical excipients, wherein the composition comprises a single population of beads, wherein each bead comprises: a) an inert core, b) an inner layer comprising topiramate, c) an outer layer comprising at least one sustained release material and at least one alkalizer. It also relates to methods of preparing such compositions and using those compositions in the treatment of neurological and/or psychiatric condition..
Cadila Healthcare Limited

Methods and systems for determining subject-specific parameters for a neuromodulation therapy

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” the neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators to control neurological state and prevent neurological signs and symptoms. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition..
Cyberonics, Inc.

Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener

This invention relates to treating prader-willi syndrome (pws) using a katp channel opener. The channel opener may be coadministered with other therapies used to treat pws, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary.
Sedogen Llc

Method and computer modeling of the interaction between and among cortical and subcortical areas in the human brain for the purpose of predicting the effect of drugs in psychiatric and cognitive diseases

Computer modeling of interactions between and among cortico and subcortical areas of the human brain predicts the effect of drugs in psychiatric and cognitive diseases on one or more clinical scales. Diseases that can be modeled include psychiatric disorders, such as schizophrenia, bipolar disorder, major depression, adhd, autism, obsessive-compulsive disorder, substance abuse and cognitive deficits therein and neurological disorders such as alzheimer's disease, mild cognitive impairment, parkinson's disease, stroke, vascular dementia, huntington's disease, epilepsy and down syndrome.

Device and phase-locking brain stimulation to electroencephalographic rhythms

The device and method for phase-locking brain stimulation to electroencephalographic rhythms improves the accuracy, specificity, and effectiveness of non-invasive brain stimulation devices by timing pulses of brain stimulation to occur in synchrony with naturally occurring brain rhythms measured at the scalp of a patient in order to treat an assortment of neurological and psychiatric conditions. The device and method provided herein improve non-invasive brain stimulation techniques by time-locking the onset of brain stimulation to the phase of naturally-occurring rhythmic oscillations of brain activity that can be recorded with electroencephalography (eeg).
Board Of Trustees Of The University Of Arkansas

2-pyridyloxy-4-ester orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders

Copolymer 1, a copolymer 1-related peptide, a copolymer 1-related polypeptide, and t cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions.. .
Yeda Research And Development Co. Ltd.

Treating various disorders using trkb agonists

Novel compounds and methods for activating the trkb receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted c5 or c6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof.
Emory University

Orexin receptor antagonists

The disclosures herein relate to novel compounds of formula wherein w, x and y1, y2, y3 and y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.. .
Heptares Therapeutics Limited

Pde9 inhibitors with imidazo triazinone backbone

This invention is directed to compounds, which are pde9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
H. Lundbeck A/s

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. .
Acorda Therapeutics, Inc.

Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

Materials and methods for modulating disc1 turnover

The invention relates to the finding that turnover of disc1 (disrupted in schizophrenia 1) is mediated by the f-box-containing protein fbxw7 (f-box/wd repeat-containing protein 7). The sequence within disc1 that binds to fbxw7 and targets disc1 for turnover by the ubiquitin-proteasome system is identified.
The University Court Of The University Of Glasgow

Pharmaceutical composition for treating or preventing neuropsychiatric disease, containing flavone-6-c-glucose derivatives as active ingredients

The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-c-glucose derivatives or galenical extracts containing flavone-6-c-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders..
Dae Hwa Pharma. Co., Ltd.

Anti-depression compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The University Of Texas System

Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

In one aspect, the invention relates to substituted thieno[2,3-b]pyridine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University

5-ht3 receptor antagonists

That are 5ht3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..

Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors

Their use as allosteric modulators of mglur5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.. .

Thiazole orexin receptor antagonists

The present invention is directed to thiazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thiazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Oxazole orexin receptor antagonists

The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Dispense event verification for dispensers

One or more techniques and/or systems are provided for dispense event verification. For example, a user verification component may be associated with a dispenser that is configured to dispense material, such as a sanitizer dispenser configured to dispense sanitizer.
Gojo Industries, Inc.,

Therapeutic intervention

Provided are methods and materials for treating a neurological, behavioural, psychological, psychiatric, or personality disorder or syndrome in an individual, which disorder or syndrome is associated with a plurality of aberrant thoughts, behaviors and/or dispositions to behaviour. The methods comprise (i) selecting an individual suffering from, or believed to suffer from, said disorder or syndrome; and (ii) selecting a set of effector junctions in the individual, wherein at least one of said aberrant thoughts, behaviors or dispositions is modifiable by modulation of transmission across the set of effector junctions; (iii) treating the individual with an agent (for example botulinum toxin or a derivative or analog thereof) or intervention which causes blockade of or interference with the set of effector junctions, wherein blockade of the set of effector junctions results in an inhibition of the plurality of aberrant thoughts, behaviors and/or dispositions associated with the disorder..
Ulc Business Plc

Diagnostic pediatric acute-onset neuropsychiatric syndrome (pans) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (pans) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (pandas) in an individual. These include enzyme linked immunosorbent assays (elisas) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor d1, dopamine receptor d2, serotonin receptor 5ht2a, and serotonin receptor 5ht2c.

Diagnostic pediatric acute-onset neuropsychiatric syndrome (pans) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (pans) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (pandas) in an individual. These include enzyme linked immunosorbent assays (elisas) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor d1, dopamine receptor d2, serotonin receptor 5ht2a, and serotonin receptor 5ht2c.

Methods of detecting neurological or neuropsychiatric diseases or conditions

This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of neurological or neuropsychiatric diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of neurological or neuropsychiatric diseases or conditions..
President And Fellows Of Harvard College

Multi-tailed lipids and uses thereof

The present invention provides multi-tailed lipid compounds, and salts and stereoisomers thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an sirna, mrna, plasmid dna, small molecule, protein, peptide).
Massachusetts Institute Of Technology

Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders

The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (cns) disorders, including depression and anxiety.. .

Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

The present invention relates to compositions and methods for treating neuropsychiatric disorders in vertebrates and humans. More specifically, the present invention provides for use of irl-1620, an endothelin-b receptor agonist, in appropriate doses to be a neuroprotective and a neuroregenerative agent.
Midwestern University

Cycloalkyl-diamines for neurodegenerative disorders

The invention is directed to the use of a compound of formula i as defined herein, a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing a compound of formula i, in treating a mammal, including a human, for a psychiatric disorder or condition selected from the group consisting of stroke, huntington's disease and amyotrophic lateral sclerosis (als).. .
Medisynergics, Llc

Antagonists of cb1 receptor

The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
Universite De Bordeaux

4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators

The disclosures herein relate to novel compounds of formula wherein r1, r2, r3 and r4 and n are defined here, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mglu5 receptor function.. .
Heptares Therapeutics Limited

Clathrin therapeutic for psychiatric and neuropsychiatric disorders

The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating a psychiatric and/or neuropsychiatric disease, condition, or disorder, in vivo or in vitro..

Abbvie Inc.

. .

Biomarker for psychiatric and neurological disorders

The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders.
Resvo Inc.

Regulatory brain specific cytoplasmic rnas (bc rnas) and methods of use thereof in diagnosis and treatment of neuropsychiatric lupus

Compositions and methods for diagnosing an increased risk of npsle are provided.. .
The Research Foundation For State University Of New York

Devices, treatment of neuropsychiatric disorders

The present disclosure relates to methods, devices and systems used for the treatment of mood, anxiety, post traumatic stress disorder, and cognitive and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“tns”). More specifically, cutaneous methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, infraorbital, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein..
The Regents Of The University Of California

Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons.
Cornell University

Compositions comprising a prostaglandin for treating neuropsychiatric conditions

The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).. .
Inceptum Research & Therapeutics, Inc.

Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

In one aspect, the invention relates to 3-benzylquinazolin-4(3h)-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..

2-hydroxymethyl-substituted orexin receptor antagonists

The present invention is directed to 2-hydroxymethyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mglur5

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Vanderbilt University

Therapeutic targeting of the mtor pathway in neurodevelopmental and neuropsychiatric disease

The present invention relates to methods of treating various neurodevelopmental and neuropsychiatric diseases which employ inhibition of the mtor pathway, particularly using mtor kinase inhibitors. It is based, at least in part, on extensive phenotypic characterization of a knock-out mouse model of caspr2, the murine ortholog of cntnap2, which indicate that the mechanism via which cntnap2 deficits lead to neuropsychiatric disorders is overactivation of the mtor pathway.
The Trustees Of Columbia Univeristy In The City Of New York

Cb2 receptor ligands for the treatment of psychiatric disorders

The present invention provides cannabinoid type 2 (cb2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-o-methylhonokiol for treating attention deficit hyperactivity disorder (adhd) and tourette's syndrome..
Ariel - University Research And Development Company, Ltd.

Substituted 1-benzylquinoxalin-2(1h) analogs as positive allosteric modulators of muscarinic acetylcholine receptor m1

The invention relates to substituted 1-benzylquinoxalin-2(1h)-one analogs, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); methods for making the compounds; pharmaceutical compositions; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.. .
Vanderbilt Univesity

Pro-neurogenic compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The University Of Texas System

Olfactory means useful in the diagnosis and treatment of mood depression

A kit of two compositions comprising the same odorants in mixtures of different proportions is used for the measurement of olfactory discrimination capacity in subjects affected by a psychiatric disorder or disease involving mood disturbance, more particularly mood depression.. .
Centre National De La Recherche Scientifique

Halo and trifluoromethyl substituted orexin receptor antagonists

The present invention is directed to halo and trifluoromethyl substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Hydroxy-substituted orexin receptor antagonists

The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Substituted pyridazine carboximide compounds

The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against alk and are useful in treating disorders related to abnormal protein kinase activities such as cancer, neurological and psychiatric diseases.. .
Xcovery Holding Company, Llc

Brush-poly (glycoamidoamine)-lipids and uses thereof

Which may assist the pgal and/or a complex of the pgal and an agent to pass through cell membranes or be taken up by cells. Also provided are compositions including a described pgal and an agent (e.g., polynucleotide, small molecule, peptide, or protein).

1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders

Wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.

Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient

Disclosed are methods, kits, and devices for diagnosing and treating psychiatric, disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a patient and treat the diagnosed and/or prognosed patient by administering a drug the patient based on the genetic marker having been identified.
Northwestern University

Modulation of activity of proneurotrophins

The present invention provides agents for inhibiting binding of a pro-neurotrophin to a vps10p-domain receptor, in particular the binding of a pro-ngf or a pro-bdnf to a sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual..
H. Lundbeck A/s

Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness

The invention relates to methods of protecting against chronic stress in a subject and treating stress sensitive disorders in a subject by antagonizing ghrelin or ghrelin receptor.. .
Massachusetts Institute Of Technology

Devices, optogenetic modulation of action potentials in target cells

Aspects of the disclosure include devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering vectors to target cells.
The Board Of Trustees Of Theleland Stanford Junior University

Galactooligosaccharide composition for use in preventing or treating cognitive dysfunction and emotional disturbances in neuropsychiatry illnesses or ageing

A galactooligosaccharide composition comprising a mixture of disaccharides, trisaccharides, a tetrasaccharide and a pentasaccharide for use in preventing or treating cognitive dysfunction and/or emotional disturbances in neuropsychiatric illnesses or ageing.. .
Clasado Inc

Sound generation system with two audio channels for treating psychological/psychiatric and neurological disorders

A sound generation system with two audio channels for treating psychological/psychiatric and neurological disorders, comprising means (g/m, md, dc, m/g mx) for generating two first audio signals, one for each audio channel (ch1, ch2), wherein each first signal is a random noise, and wherein the two first signals are not correlated to each other and define a relative reference sound level. The generation system comprises means (g/m, md, dc, mx) for adding to both the first signals a second signal at a sound level having amplitude between +/−12 db with respect to the relative reference sound level..

Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the hpa axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the hpa axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin..
Embera Neurotherapeutics, Inc.

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company

Use of electroretinography (erg) for the assessment of psychiatric disorders

Methods for the diagnosis, prognosis, patient stratification and prediction of pharmacological response in patients afflicted by psychiatric disorders based on electroretinography (erg) parameters are described.. .
UniversitÉ Laval

Mlk inhibitors and methods of use

Provided are compounds having an inhibitory effect on mixed lineage kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by mixed lineage kinase inhibition.
The University Of Rochester

Methods and pharmaceutical compositions for the treatment of symptoms of anxiety and panic using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations

The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist.

Methods and pharmaceutical compositions for the treatment of symptoms of anxiety and panic using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations

The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist.

Systems and methods for generating biomarkers based on multivariate classification of functional imaging and associated data

Systems and methods for generating biomarkers associated with neuropsychiatric disorders, neurodevelopmental disorders, neurobehavioral disorders, or other neurological disorders are described. In general, the biomarkers are generated based on correlations between functional imaging data and clinical acquired from a subject, as computed using a multivariate classifier.
The Brigham And Women's Hospital

Substituted pyridizinone derivatives as pde10 inhibitors

The present invention is directed to substituted pyridizinone compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (pde10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction..
Merck Sharp & Dohme Corp.

2-pyridyloxy-4-ether orexin receptor antagonists

The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.

Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same

The present invention relates to a composition for preventing or treating a psychiatric disorder comprising a phenyl carbamate compound and a method for preventing or treating a psychiatric disorder therewith. The present invention provides anti-anxiety activity and protections against seizure and bipolar disorder, such that it may be effectively used for preventing or treating various psychiatric disorders related to mood disorder or resulting convulsion..
Bio-pharm Solutions Co., Ltd.

Potent and selective inhibitors of monoamine transporters; making; and use thereof

Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (da), serotonin (5-ht), and/or norepinephrine (ne) reuptake via their respective transporters, dat, sert and net.
The United States Of America, As Represented By Th Secretary, Department Of Health And Human Service

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

Method to increase bioavailability of the delta-opioid receptor for management of pain and neuropsychiatric disorders

Described herein is a method to induce surface trafficking of the delta-opioid receptor (dor) and its applications, including, leveraging the antinociceptive potential of dor agonists to treaty neurologic disorders and to be analgesics without the adverse consequences normally associated with chronic treatment by mor agonists by inducing surface trafficking of the delta-opioid receptor (dor) and screening compounds to identify additional targets for stimulated dor delivery.. .
Carnegie Mellon University, A Pennsylvania Non-profit Corporation

Determination of neuropsychiatric therapy mechanisms of action

A computer implemented method, apparatus, and computer program product of determining mechanisms of action for therapies. A first set of brain scans for each subject in a plurality of subjects generated at a first time period and a second set of brain scans for each subject generated at a second time period are received.
International Business Machines Corporation

Novel inhibitor compounds of phosphodiesterase type 10a

The compounds of the formula i, the n-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10a. Thus, the invention also relates to the use of the compounds of the formula i, the n-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders..

Polyamine-fatty acid derived lipidoids and uses thereof

The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of formula (i) or (ii)) and methods of preparing the lipidoids. A described lipidoid includes r—c(═o)—o— moieties (where r is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids.
Massachusetts Institute Of Technology

Compositions and methods for treating psychiatric disorders

Methods of treating psychiatric disorders are provided which include administration of one or more anti-epileptic agents and, optionally, one or more a psychostimulants. Also provided are pharmaceutical compositions comprising, in combination, one or more anti-epileptic agents and one or more psychostimulants.
Gosforth Centre (holdings) Pty Ltd.